Global Non-Small Cell Lung Cancer Diagnostics Market is expected to grow with a CAGR of 13.2% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.
The global non-small cell lung cancer diagnostics market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.
The major players dealing in the global non-small cell lung cancer diagnostics market are introducing a strong range of products provider along with launching new certificates and adopting strategic initiatives such as acquisition, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.
Abbott Laboratories is the dominating player in the global non-small cell lung cancer diagnostics market. The other key players existing in the market are F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix.
Abbott Laboratories, founded in the year 1903, headquarter is in Illinois, U.S. The company is focused on delivering instruments and assay solutions to provide early diagnosis of diseases and for selection of appropriate therapies, and to monitor diseases recurrence. The company has several product categories, including featured products, instrumentation, infectious disease, informatics, oncology, genetics, and genomics in which instrumentation, infectious disease, oncology is the market-focused category.
The company has a wide presence across Asia-Pacific, Europe, America, South Africa, and the Middle East.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd, founded in the year 1896, is headquartered in Basel, Switzerland. The main focus of the company is on developing and integrating diagnostic solutions covering molecular diagnostics, clinical chemistry, immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation, and IT and decision support solutions. The company operates its business via several business segments, including pharmaceuticals, diagnostics in which diagnostics are the market-focused segment.
The company has a presence across Europe, North America, Asia-Pacific, Africa.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated was founded in the year 1967, headquartered in New Jersey, U.S. The main focus of the company is on providing diagnostics testing, information, and services to patients, healthcare providers, pharmaceutical companies, and life insurance companies. The company has product categories in segments, including solutions for physicians and hospitals, medical conditions, and a focus on speciality, in which medical conditions is the market-focused category.
The company has a presence across Europe, North America, Asia-Pacific.
Global Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
North America Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Europe Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028